TCM Biotech International Corp. (TPEX:4169)

Market Cap	10.54B +207.8%
Revenue (ttm)	685.49M +2.8%
Net Income	19.17M -8.8%
EPS	0.32 -11.1%
Shares Out	59.05M
PE Ratio	549.83
Forward PE	n/a
Dividend	0.35 (0.20%)
Ex-Dividend Date	n/a

Volume	349,081
Average Volume	422,572
Open	183.00
Previous Close	178.50
Day's Range	167.00 - 183.00
52-Week Range	43.65 - 250.00
Beta	0.04
RSI	37.23
Earnings Date	Apr 17, 2026

About TCM Biotech International

TCM Biotech International Corp., a biotech company, engages in the research and development of drugs for liver diseases. The company offers medical devices, such as therapy for osteoarthritis, intra-articular implant of hyaluronic acid, automated blood cell separator, absorbable adhesion barrier material, prosthetic and orthotic accessory, and pellefeel mask pressure relief pad; and pharmaceuticals, including iron supplement, therapeutic agent for urinary system, expectorant/mucolytic agent, anticancer drug, antihypertensive drug, and antidiabe...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1998
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 4169

Financial Performance

In 2025, TCM Biotech International's revenue was 685.49 million, an increase of 2.84% compared to the previous year's 666.53 million. Earnings were 19.17 million, a decrease of -8.76%.